Search

Displaying results 6441 - 6450 of 10000 in total
  1. Drug

    Tucidinostat

    go.drugbank.com/drugs/DB06334
    Investigational

  2. Drug

    Carotuximab

    go.drugbank.com/drugs/DB06322
    Investigational

  3. Drug

    CP-39,332

    go.drugbank.com/drugs/DB09193
    Experimental

    It is part of a group of monoamine reuptake inhibitor stereoisomers including tametraline (1R,4S-), CP-24,442 (1S,4R-), CP-22,185 (cis-), and CP-22,186 that show varying efficiency.

  4. Drug

    PHB-050

    go.drugbank.com/drugs/DB32061
    Experimental

    [L54988] It is under investigation for the treatment of multiple atopic diseases, including food allergies, asthma, and atopic dermatitis.[L54988]

  5. Drug

    BBV152

    go.drugbank.com/drugs/DB15847
    Investigational

    Animal studies in mice, rats, and rabbits reported BBV152 immunogenicity at two separate antigen concentrations with both types of adjuvants. … Thus, as of July 2020, BBV152 is in Phase 1/2 clinical trials assessing safety and immunogenicity in humans (NCT04471519).

  6. Drug

    AeroLEF

    go.drugbank.com/drugs/DB05000
    Investigational

    AeroLEF™ is in development for the treatment of moderate to severe pain, including cancer pain.

  7. Drug

    Gotistobart

    go.drugbank.com/drugs/DB19100
    Investigational

    Gotistobart is under investigation in clinical trial NCT05671510 (ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors).

  8. Drug

    Livoletide

    go.drugbank.com/drugs/DB15188
    Investigational

    Livoletide is under investigation in clinical trial NCT03790865 (Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome).

  9. Drug

    Bixalomer

    go.drugbank.com/drugs/DB15200
    Investigational

    Bixalomer is under investigation in clinical trial NCT01115985 (A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Atorvastatin in Healthy Volunteers).

  10. Drug

    RTA 744

    go.drugbank.com/drugs/DB05920
    Investigational

    RTA 744 is a novel anthracycline derivative that crosses the blood-brain barrier and shows significant potential for the treatment of primary and metastatic brain cancers. Anthracyclines are one of the most broadly used and effective cla...